Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict Survival

Estimated 1-year survival for a first transplant, under 18 years old, CMV-negative patient with a 25-year-old donor. The patient is assumed to be White with a KPS of 90-100, transplanted in 2003-2006 using myeloablative conditioning and tacrolimus/methotrexate as GVHD prophylaxis. The 21 groups cluster (per Table 2) as: well matched (thin/blue lines); partially matched (thick/red lines); and mismatched (medium/green lines). Right panel in color for website display.

Estimated survival for different patients undergoing a first transplant. Patients are all assumed to be CMV negative, White, with a KPS of 90-100, transplanted in 2003-2006 receiving tacrolimus/methotrexate as GVHD prophylaxis and a 25-year-old donor. All transplants are assumed myeloablative except the 55-year-old late MDS patient who was assumed to have a reduced-intensity transplant. Patients' age, disease, and disease stage are as shown in each panel.

Estimated 5-year survival for different patients undergoing a first transplant. Patients are assumed to be CMV negative, White, with a KPS of 90-100, transplanted in 2003-2006 receiving tacrolimus/methotrexate as GVHD prophylaxis and a 25-year-old donor. All transplants are assumed myeloablative except the 55-year-old late MDS patient who was assumed to have a reduced-intensity transplant. Patients' age, disease, and disease stage are as shown in each panel.